Home > Research > Publications & Outputs > "AIDS is not a business"

Research

Links

Text available via DOI:

Keywords

View graph of relations

"AIDS is not a business": a study in global corporate social responsibility

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

"AIDS is not a business": a study in global corporate social responsibility. / Flanagan, William; Whiteman, Gail.
In: Journal of Business Ethics, Vol. 73, No. 1, 73, 06.2007, p. 65-75.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Flanagan, W & Whiteman, G 2007, '"AIDS is not a business": a study in global corporate social responsibility', Journal of Business Ethics, vol. 73, no. 1, 73, pp. 65-75. https://doi.org/10.1007/s10551-006-9198-y

APA

Flanagan, W., & Whiteman, G. (2007). "AIDS is not a business": a study in global corporate social responsibility. Journal of Business Ethics, 73(1), 65-75. Article 73. https://doi.org/10.1007/s10551-006-9198-y

Vancouver

Flanagan W, Whiteman G. "AIDS is not a business": a study in global corporate social responsibility. Journal of Business Ethics. 2007 Jun;73(1):65-75. 73. Epub 2006 Dec 14. doi: 10.1007/s10551-006-9198-y

Author

Flanagan, William ; Whiteman, Gail. / "AIDS is not a business" : a study in global corporate social responsibility. In: Journal of Business Ethics. 2007 ; Vol. 73, No. 1. pp. 65-75.

Bibtex

@article{93a6748cdba74a54b6d2b794d022c610,
title = "{"}AIDS is not a business{"}: a study in global corporate social responsibility",
abstract = "At the end of the 1990s, Brazil was faced with a potentially explosive HIV/AIDS epidemic. Through an innovative and multifaceted campaign, and despite initial resistance from multinational pharmaceutical companies, the government of Brazil was able to negotiate price reductions for HIV medications and develop local production capacity, thereby averting a public health disaster. Using interview data and document analysis, the authors show that the exercise of corporate social responsibility can be viewed in practice as a dynamic negotiation and an interaction between multiple actors. Action undertaken in terms of voluntary CSR alone may be insufficient. This finding highlights the importance of a strong role for national governments and international organizations to pressure companies to perform better.",
keywords = "Brazil , compulsory licensing , corporate social responsibility, developing countries, HIV/AIDS, multinational pharmaceutical companies, patents , TRIPS , WTO",
author = "William Flanagan and Gail Whiteman",
year = "2007",
month = jun,
doi = "10.1007/s10551-006-9198-y",
language = "English",
volume = "73",
pages = "65--75",
journal = "Journal of Business Ethics",
issn = "0167-4544",
publisher = "Springer Netherlands",
number = "1",

}

RIS

TY - JOUR

T1 - "AIDS is not a business"

T2 - a study in global corporate social responsibility

AU - Flanagan, William

AU - Whiteman, Gail

PY - 2007/6

Y1 - 2007/6

N2 - At the end of the 1990s, Brazil was faced with a potentially explosive HIV/AIDS epidemic. Through an innovative and multifaceted campaign, and despite initial resistance from multinational pharmaceutical companies, the government of Brazil was able to negotiate price reductions for HIV medications and develop local production capacity, thereby averting a public health disaster. Using interview data and document analysis, the authors show that the exercise of corporate social responsibility can be viewed in practice as a dynamic negotiation and an interaction between multiple actors. Action undertaken in terms of voluntary CSR alone may be insufficient. This finding highlights the importance of a strong role for national governments and international organizations to pressure companies to perform better.

AB - At the end of the 1990s, Brazil was faced with a potentially explosive HIV/AIDS epidemic. Through an innovative and multifaceted campaign, and despite initial resistance from multinational pharmaceutical companies, the government of Brazil was able to negotiate price reductions for HIV medications and develop local production capacity, thereby averting a public health disaster. Using interview data and document analysis, the authors show that the exercise of corporate social responsibility can be viewed in practice as a dynamic negotiation and an interaction between multiple actors. Action undertaken in terms of voluntary CSR alone may be insufficient. This finding highlights the importance of a strong role for national governments and international organizations to pressure companies to perform better.

KW - Brazil

KW - compulsory licensing

KW - corporate social responsibility

KW - developing countries

KW - HIV/AIDS

KW - multinational pharmaceutical companies

KW - patents

KW - TRIPS

KW - WTO

U2 - 10.1007/s10551-006-9198-y

DO - 10.1007/s10551-006-9198-y

M3 - Journal article

VL - 73

SP - 65

EP - 75

JO - Journal of Business Ethics

JF - Journal of Business Ethics

SN - 0167-4544

IS - 1

M1 - 73

ER -